<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04846881</url>
  </required_header>
  <id_info>
    <org_study_id>1346-0012</org_study_id>
    <secondary_id>2020-003744-84</secondary_id>
    <nct_id>NCT04846881</nct_id>
  </id_info>
  <brief_title>Clinical Trial of BI 425809 Effect on Cognition and Functional Capacity in Schizophrenia (CONNEX-2)</brief_title>
  <official_title>A Phase III Randomized, Double-blinded, Placebo-controlled Parallel Group Trial to Examine the Efficacy and Safety of BI 425809 Once Daily Over 26 Week Treatment Period in Patients With Schizophrenia (CONNEX-2)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults with schizophrenia. Schizophrenia can affect the way a person&#xD;
      thinks, their memory and their mental functioning. Examples include struggling to remember&#xD;
      things, or to read a book or pay attention to a movie. Some people have difficulty&#xD;
      calculating the right change or planning a trip so that they arrive on time. The purpose of&#xD;
      this study is to find out whether a medicine called BI 425809 improves learning and memory in&#xD;
      people with schizophrenia.&#xD;
&#xD;
      Participants are put into two groups randomly, which means by chance. One group takes BI&#xD;
      425809 tablets and the other group takes placebo tablets. Placebo tablets look like BI 425809&#xD;
      tablets but do not contain any medicine. Participants take a tablet once a day for 26 weeks.&#xD;
      In addition, all participants take their normal medication for schizophrenia.&#xD;
&#xD;
      During this time, doctors regularly test learning and memory of the participants by use of&#xD;
      questionnaires, interviews, and computer tests. The results of the mental ability tests are&#xD;
      compared between the groups.&#xD;
&#xD;
      Participants are in the study for about 8 months. During this time, they visit the study site&#xD;
      about 15 times and get about 3 phone calls from the study team. The doctors also regularly&#xD;
      check participants' health and take note of any unwanted effects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 7, 2021</start_date>
  <completion_date type="Anticipated">May 3, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 5, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in overall composite T-score of the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery (MCCB) after 26 weeks of treatment</measure>
    <time_frame>at baseline and at week 26</time_frame>
    <description>MCCB comprises 10 tests, which assess 7 cognitive domains, including speed of processing, attention vigilance, working memory, verbal learning, visual learning, reasoning and problem solving, and social cognition</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in the Schizophrenia Cognition Rating Scale (SCoRS) interviewer total score after 26 weeks of treatment</measure>
    <time_frame>at baseline and at week 26</time_frame>
    <description>SCoRS is a 20-item interview-based assessment of cognitive deficits and the degree to which they affect day-to-day functioning. Each item is rated on a 4-point scale. Higher ratings reflect a greater degree of impairment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 26 in the adjusted total time in the Virtual Reality Functional Capacity Assessment Tool (VRFCAT)</measure>
    <time_frame>at baseline and at week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 26 in the T-score of the number of correct responses on Tower of London (ToL) test</measure>
    <time_frame>at baseline and at week 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from screening visit 1a to Week 24 in Patient Reported Experience of Cognitive Impairment in Schizophrenia (PRECIS) total score</measure>
    <time_frame>up to 24 weeks</time_frame>
    <description>PRECIS is a patient reported outcome (PRO) for recording patients' subjective experience of Cognitive Impairment Associated with Schizophrenia (CIAS). The questionnaire contains 28 items covering 6 domains: Memory (6 items), communication (4 items), self-control (3 items), executive function (4 items), attention (6 items), and sharp thinking (3 items). Two additional items assess the overall degree of bother associated with all domains. Questions are answered via a 5-category Likert scale, with higher scores corresponding to worse patient experience. The Total Score is derived by calculating the simple average score of the first 26 items.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">586</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>BI 425809</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 425809</intervention_name>
    <description>BI 425809</description>
    <arm_group_label>BI 425809</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria&#xD;
&#xD;
          -  Signed and dated written informed consent.&#xD;
&#xD;
          -  Male or female patients who are 18-50 years (inclusive) of age at time of consent.&#xD;
&#xD;
          -  Diagnosis of schizophrenia utilizing Diagnostic and Statistical Manual of Mental&#xD;
             Disorders 5th Edition (DSM-5).&#xD;
&#xD;
             -- Patients must be clinically stable and in the residual (non-acute) phase of their&#xD;
             illness with no hospitalization or increase level of care due to worsening of&#xD;
             schizophrenia in the past 12 weeks or no uncontrolled positive symptoms.&#xD;
&#xD;
          -  Patients should have functional impairment in day-to-day activities per investigator&#xD;
             judgement.&#xD;
&#xD;
          -  Patients maintained on current antipsychotic treatment for at least 12 weeks and on&#xD;
             current dose for at least 35 days prior to randomization.&#xD;
&#xD;
          -  Patients with any other concomitant psychoactive medications (except for&#xD;
             anticholinergics) need to be maintained on same drug for at least 12 weeks and on&#xD;
             current dose/ regimen for at least 35 days prior to randomization.&#xD;
&#xD;
          -  Women of childbearing potential must use highly effective methods of birth control.&#xD;
&#xD;
          -  Have a study partner who interacts with the patient on a regular basis. Further&#xD;
             inclusion criteria apply.&#xD;
&#xD;
        Exclusion criteria&#xD;
&#xD;
          -  Patient with current DSM-5 diagnosis other than Schizophrenia.&#xD;
&#xD;
          -  Cognitive impairment due to other causes, or patients with dementia.&#xD;
&#xD;
          -  Severe movement disorders.&#xD;
&#xD;
          -  Any suicidal behavior in past year or suicidal ideation in the past 3 months.&#xD;
&#xD;
          -  History of moderate or severe substance use disorder within the last 12 months prior&#xD;
             to informed consent.&#xD;
&#xD;
          -  Positive urine drug screen.&#xD;
&#xD;
          -  Patients who were treated with Clozapine, stimulants, ketamine or electroconvulsive&#xD;
             therapy within 6 months prior to randomization.&#xD;
&#xD;
          -  Current participation in any investigational drug trial.&#xD;
&#xD;
          -  Cognitive Remediation Therapy within 12 weeks prior to screening.&#xD;
&#xD;
          -  Initiation or change in any type or frequency of psychotherapy within 12 weeks prior&#xD;
             to randomization.&#xD;
&#xD;
          -  Any clinically significant finding or condition that would jeopardize the patient´s&#xD;
             safety while participating in the trial or their capability to participate in the&#xD;
             trial.&#xD;
&#xD;
          -  Haemoglobin (Hb) below lower limit of normal .&#xD;
&#xD;
          -  History of haemolytic anaemia, red blood cell (RBC) membrane diseases, known&#xD;
             Glucose-6-phosphate dehydrogenase deficiency, anaemia of any cause or patients&#xD;
             planning to donate blood.&#xD;
&#xD;
          -  Severe renal impairment.&#xD;
&#xD;
          -  Indication of liver disease.&#xD;
&#xD;
          -  Any documented active or suspected malignancy or history of malignancy within 5 years.&#xD;
&#xD;
          -  Women who are pregnant, nursing, or who plan to become pregnant while in the trial.&#xD;
&#xD;
        Further exclusion criteria apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>CiTrials</name>
      <address>
        <city>Bellflower</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Diane Highum</last_name>
      <phone>+001(562)748-4999</phone>
      <email>Highum@citrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ATP Clinical Research, Inc.</name>
      <address>
        <city>Costa Mesa</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gustavo Alva</last_name>
      <phone>+001(714)277-4472</phone>
      <email>galva@atpcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ASCLEPES Research Centers, P.C. dba Alliance Research</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Zarate-Rowell</last_name>
      <phone>+001(562)548-8500</phone>
      <email>erowell@allianceforresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Collaborative Neuroscience Research</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Armen Goenjian</last_name>
      <phone>+001(310)523-4200</phone>
      <email>armengoenjian@cnstrial.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Optimus U Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yaneicy Gonzalez-Rojas</last_name>
      <phone>+001(305)702-0024</phone>
      <email>drgonzalez@optimusu.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Altea Research Institute</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jelena Kunovac</last_name>
      <phone>+001(702)527-7401</phone>
      <email>kunovacmd@sbcglobal.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Neurobehavioral Research, Inc.</name>
      <address>
        <city>Cedarhurst</city>
        <state>New York</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronald Brenner</last_name>
      <phone>+001(516)295-7230</phone>
      <email>rbrenner@nbrresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwest Clinical Research Center</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arifulla Khan</last_name>
      <phone>+001(425)453-0404</phone>
      <email>akhan@nwcrc.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fundación FunDaMos para la asistencia e investigación en p</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daniel Mosca</last_name>
      <phone>+541149038776</phone>
      <email>danimosca07@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>SERES Neurociencia Cognitiva Aplicada</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Caches</last_name>
      <phone>+54(11)4806-0999</phone>
      <email>macaches@centroseres.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEMEC - Centro Multidisciplinar de Estudos Clínicos</name>
      <address>
        <city>São Bernardo do Campo</city>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cintia Perico</last_name>
      <phone>551149304243</phone>
      <email>cazevedomarques@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Biomedica Research Group</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergio Gloger</last_name>
      <phone>0056222045686</phone>
      <email>sergio.gloger@biomedica.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Charles Perrens</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Misdrahi</last_name>
      <phone>+33(0)556563434</phone>
      <email>dmisdrahi@ch-perrens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP la Colombière</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jérôme Attal</last_name>
      <phone>+33(0)467339702</phone>
      <email>j-attal@chu-montpellier.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>HOP Nord</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eric Fakra</last_name>
      <phone>+33(0)477828852</phone>
      <email>eric.fakra@chu-st-etienne.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Debrecen Hospital</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ede Frecska</last_name>
      <phone>+3652255240</phone>
      <email>frecska.ede@med.unideb.hu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toyota Memorial Hospital</name>
      <address>
        <city>Aichi, Toyota</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kohei Kawase</last_name>
      <phone>+81565280100</phone>
      <email>kohei_kawase_aa@mail.toyota.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Uematsu Mental Clinic</name>
      <address>
        <city>Fukuoka, Chikugo</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Uematsu</last_name>
      <phone>+81942807890</phone>
      <email>clinic.uematsu@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hirota Clinic</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susumu Hirota</last_name>
      <phone>+81942372595</phone>
      <email>ponhiro21@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suwa Red Cross Hospital</name>
      <address>
        <city>Nagano, Suwa</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fumi Maruyama</last_name>
      <phone>+81266526111</phone>
      <email>fmaruyama@pj8.so-net.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nara Medical University Hospital</name>
      <address>
        <city>Nara, Kashihara</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Takahira Yamauchi</last_name>
      <phone>+81744223051</phone>
      <email>tyama@naramed-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Inuo Hospital</name>
      <address>
        <city>Saga, Tosu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Akifumi Inuo</last_name>
      <phone>+81942827007</phone>
      <email>aki@inuo.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Young-Chul Chung</last_name>
      <phone>82632502185</phone>
      <email>chungyc@jbnu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jun Soo Kwon</last_name>
      <phone>82220722972</phone>
      <email>kwonjs@snu.ac.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum Groningen</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iris Sommer</last_name>
      <phone>+31503612132</phone>
      <email>i.e.c.sommer@umcg.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Maastricht Universitair Medisch Centrum</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thérèse Van Amelsvoort</last_name>
      <phone>+31433884077</phone>
      <email>t.vanamelsvoort@maastrichtuniversity.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Chile</country>
    <country>France</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 13, 2021</study_first_submitted>
  <study_first_submitted_qc>April 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 15, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BI 425809</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;.&#xD;
Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

